BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 35190273)

  • 1. Optimal exposure targets for vancomycin in the treatment of neonatal coagulase-negative Staphylococcus infection: A retrospective study based on electronic medical records.
    Chen Q; Wan J; Shen W; Lin W; Lin X; Huang Z; Lin M; Chen Y
    Pediatr Neonatol; 2022 May; 63(3):247-254. PubMed ID: 35190273
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of Therapeutic Vancomycin Monitoring in Taiwan.
    Chen TT; Liu MP; Sun HC
    Microbiol Spectr; 2022 Apr; 10(2):e0156221. PubMed ID: 35412391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Implementation of vancomycin AUC/MIC dosing vs traditional trough dosing and incidence of acute kidney injury at a rural community hospital.
    McClure S; McElroy L; Gugkaeva Z
    Am J Health Syst Pharm; 2024 May; 81(11):e283-e288. PubMed ID: 38253056
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Are Vancomycin Trough Concentrations of 15 to 20 mg/L Associated With Increased Attainment of an AUC/MIC ≥ 400 in Patients With Presumed MRSA Infection?
    Hale CM; Seabury RW; Steele JM; Darko W; Miller CD
    J Pharm Pract; 2017 Jun; 30(3):329-335. PubMed ID: 27074786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Establishment of an AUC
    Chavada R; Ghosh N; Sandaradura I; Maley M; Van Hal SJ
    Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28242672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The monitoring of vancomycin: a systematic review and meta-analyses of area under the concentration-time curve-guided dosing and trough-guided dosing.
    Tsutsuura M; Moriyama H; Kojima N; Mizukami Y; Tashiro S; Osa S; Enoki Y; Taguchi K; Oda K; Fujii S; Takahashi Y; Hamada Y; Kimura T; Takesue Y; Matsumoto K
    BMC Infect Dis; 2021 Feb; 21(1):153. PubMed ID: 33549035
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of Vancomycin Area-Under-the-Curve Dosing Versus Trough Target-Based Dosing in Obese and Nonobese Patients With Methicillin-Resistant
    Covvey JR; Erickson O; Fiumara D; Mazzei K; Moszczenski Z; Slipak K; Nemecek BD; Zimmerman DE; Guarascio AJ
    Ann Pharmacother; 2020 Jul; 54(7):644-651. PubMed ID: 31888350
    [No Abstract]   [Full Text] [Related]  

  • 8. Determination of a vancomycin nephrotoxicity threshold and assessment of target attainment in hematology patients.
    Wong S; Selby PR; Reuter SE
    Pharmacol Res Perspect; 2024 Aug; 12(4):e1231. PubMed ID: 38940223
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost comparison of AUC:MIC- versus trough-based vancomycin monitoring for MRSA bacteremia.
    Beccari MV; Seabury RW; Mogle BT; Kufel WD; Miller CD; Steele JM
    J Am Pharm Assoc (2003); 2020; 60(5):729-733. PubMed ID: 32224054
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Emperor's New Clothes: PRospective Observational Evaluation of the Association Between Initial VancomycIn Exposure and Failure Rates Among ADult HospitalizEd Patients With Methicillin-resistant Staphylococcus aureus Bloodstream Infections (PROVIDE).
    Lodise TP; Rosenkranz SL; Finnemeyer M; Evans S; Sims M; Zervos MJ; Creech CB; Patel PC; Keefer M; Riska P; Silveira FP; Scheetz M; Wunderink RG; Rodriguez M; Schrank J; Bleasdale SC; Schultz S; Barron M; Stapleton A; Wray D; Chambers H; Fowler VG; Holland TL
    Clin Infect Dis; 2020 Apr; 70(8):1536-1545. PubMed ID: 31157370
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Area under the concentration-time curve to minimum inhibitory concentration ratio as a predictor of vancomycin treatment outcome in methicillin-resistant Staphylococcus aureus bacteraemia.
    Jung Y; Song KH; Cho Je; Kim HS; Kim NH; Kim TS; Choe PG; Chung JY; Park WB; Bang JH; Kim ES; Park KU; Park SW; Kim HB; Kim NJ; Oh MD
    Int J Antimicrob Agents; 2014 Feb; 43(2):179-83. PubMed ID: 24315788
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vancomycin AUC24/MIC ratio in patients with complicated bacteremia and infective endocarditis due to methicillin-resistant Staphylococcus aureus and its association with attributable mortality during hospitalization.
    Brown J; Brown K; Forrest A
    Antimicrob Agents Chemother; 2012 Feb; 56(2):634-8. PubMed ID: 22123681
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of the clinical efficacy of vancomycin with the novel pharmacokinetic parameter area under the trough level (AUTL) in elderly patients with hospital-acquired pneumonia.
    Fukumori S; Tsuji Y; Mizoguchi A; Kasai H; Ishibashi T; Iwamura N; To H
    J Clin Pharm Ther; 2016 Aug; 41(4):399-402. PubMed ID: 27144370
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vancomycin exposure in patients with methicillin-resistant Staphylococcus aureus bloodstream infections: how much is enough?
    Lodise TP; Drusano GL; Zasowski E; Dihmess A; Lazariu V; Cosler L; McNutt LA
    Clin Infect Dis; 2014 Sep; 59(5):666-75. PubMed ID: 24867791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical validation of the two-point method for predicting vancomycin AUC based on peak and trough plasma concentrations.
    Wang L; Lin X; Wang L; Ye H; Lin Y; Ruan J; Shi S
    Int J Clin Pharm; 2022 Dec; 44(6):1325-1331. PubMed ID: 36136207
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vancomycin Trough Concentration as a Predictor of Clinical Outcomes in Patients with Staphylococcus aureus Bacteremia: A Meta-analysis of Observational Studies.
    Prybylski JP
    Pharmacotherapy; 2015 Oct; 35(10):889-98. PubMed ID: 26497475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Coagulase negative staphylococcal sepsis in neonates: do we need to adapt vancomycin dose or target?
    Padari H; Oselin K; Tasa T; Metsvaht T; Lõivukene K; Lutsar I
    BMC Pediatr; 2016 Dec; 16(1):206. PubMed ID: 27931193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of area under the concentration-time curve to minimum inhibitory concentration ratio on vancomycin treatment outcomes in methicillin-resistant Staphylococcus aureus bacteraemia.
    Song KH; Kim HB; Kim HS; Lee MJ; Jung Y; Kim G; Hwang JH; Kim NH; Kim M; Kim CJ; Choe PG; Chung JY; Park WB; Kim ES; Park KU; Kim NJ; Kim EC; Oh MD
    Int J Antimicrob Agents; 2015 Dec; 46(6):689-95. PubMed ID: 26555059
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of initial vancomycin pharmacokinetic/pharmacodynamic parameters on the clinical and microbiological outcomes of methicillin-resistant Staphylococcus aureus bacteremia in children.
    Yoo R; So H; Seo E; Kim M; Lee J
    PLoS One; 2021; 16(4):e0247714. PubMed ID: 33793589
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Implementation of a two-point pharmacokinetic AUC-based vancomycin therapeutic drug monitoring approach in patients with methicillin-resistant Staphylococcus aureus bacteraemia.
    Mogle BT; Steele JM; Seabury RW; Dang UJ; Kufel WD
    Int J Antimicrob Agents; 2018 Dec; 52(6):805-810. PubMed ID: 30176357
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.